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ABSTRACT
Background and Objectives: The thioredoxin (TRx) system is a ubiquitous thiol oxidoreductase pathway that regulates 
cellular reduction/oxidation status. Although endothelial cell (EC) hypoxic damage is one of the important pathophysiologic 
mechanisms of ischemic heart disease, its relationship to the temporal expression pattern of the TRx system has not yet been 
elucidated well. The work presented here was performed to define the expression pattern of the TRx system and its correlation 
with cellular apoptosis in EC lines in hypoxic stress. These results should provide basic clues for applying aspects of the TRx 
system as a therapeutic molecule in cardiovascular diseases. Subjects and Methods: Hypoxia was induced with 1% O2, gen-
erated in a BBL GasPak Pouch (Becton Dickinson, Franklin Lakes, NJ, USA) in human endothelial progenitor cells (hEPC) 
and human umbilical vein endothelial cells (HUVEC). Apoptosis of these cells was confirmed by Annexin-V: Phycoerythrin 
flow cytometry. Expression patterns of TRx; TRx reductase; TRx interacting protein; and survival signals, such as Bcl-2 and 
Bax, in ECs under hypoxia were checked. Results: Apoptosis was evident after hypoxia in the two cell types. Higher TRx ex-
pression was observed at 12 hours after hypoxia in hEPCs and 12, 36, 72 hours of hypoxia in HUVECs. The expression pat-
terns of the TRx system components showed correlation with EC apoptosis and cell survival markers. Conclusion: Hypoxia 
induced significant apoptosis and its related active changes of the TRx system were evident in human EC lines. If the cellular 
impact of TRx expression pattern in various cardiovascular tissues under hypoxia or oxidative stress was studied meticulous-
ly, the TRx system could be applied as a new therapeutic target in cardiovascular diseases, such as ischemic heart disease or 
atherosclerosis. (Korean Circ J 2010;40:651-658)
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Introduction
Oxidative stress is associated with various pathophysolog-
ical states, such as chronic inflammatory diseases, malignan-
cies, and neurodegenerative disorders.
1-3) A number of studies 
have recently reported that oxidative stress also has impor-
tant roles in the development and advance of hypertension, 
atherosclerosis, myocardial ischemia, and restenosis after co-
ronary intervention.
3-5) There are various kinds of reactive oxy-
gen species (ROS) that are correlated with some cardiovascu-
lar diseases, such as nitric oxide (NO·), superoxide (O2·-), hy-
drogen peroxide (H2O2), and peroxinitrite (ONOO·-).
3) NO· is 
normally produced by endothelial nitric oxide synthase (NOS) 
in the vascular endothelium, and inducible NOS is expressed 
in macrophages and smooth muscle cells. Superoxide is gen-
erated by a one electron reduction of oxygen by various forms 
of oxidases such as xanthine oxidase, Nicotinamide Adenine 
Dinucleotide Phosphate (NADPH) oxidase, mitochondrial 
cytochrome P450 monooxygenase, heme oxygenase, and li-
poxygenase.
3) Peroxinitrite is rapidly generated by the reaction 
of NO· with O2·-.
3) 
Because ROS have various harmful effects on subcellular or-
ganelles, a counterpart system to limit ROS action, known as 652   Thioredoxin System Expression in EPC and Endothelial Cells
the antioxidative system, is essential for cellular survival.
The thioredoxin (TRx) system is one of the crucial antioxid-
ative pathways and is a thiol-reducing system which is com-
posed of TRx, TRx reductase (TRxR), and TRx interacting 
protein (TxNip). It reduces oxidized cystein groups on pro-
teins through an interaction with the redox-active center of 
TRx.
6) TRx reduces the oxidized form of TRx peroxidase, and 
the reduced TRx eliminates ROS. 
Endothelial cells (ECs) of the arterial intima constitute the 
crucial contact surface with blood. ECs and possess many hi-
ghly regulated mechanisms to maintain vascular homeosta-
sis that often go awry during the pathogenesis of vascular dis-
eases. For example, ECs show antithrombotic action via ex-
pression of prostacyclin, heparan sulfate proteoglycan, and pla-
sminogen activator inhibitor-1.
9) ECs also secrete NO to con-
trol vascular tone and contractility. During EC desquamat-
ion, mobilized human endothelial progenitor cells (hEPC) 
from bone marrow populate the injured intima area.
9) This 
function is closely related with the, severity of atherosclero-
sis, diabetes mellitus, smoking and age.
10) TRx is expressed 
ubiquitously in ECs and protects ECs from various kinds of 
oxidative stresses.
11) H2O2 increases TRx expression in ECs and 
low concentrations of H2O2 protect ECs from apoptosis by in-
duction of TRx overexpression; however, high concentra-
tions of H2O2 will exhaust the TRx reservoir and eventually 
induce EC apoptosis.
12) Up to now, there has been little data 
available on the temporal expression pattern of the TRx sys-
tem and its correlation with apoptosis in ECs under hypoxia. 
In this report, we describe the hypoxia-induced temporal ex-
pression of the TRx system, its correlation with apoptosis, and 
survival signal changes in hEPCs and human umbilical vein 
endothelial cells (HUVECs). We expected that this work will 
provide us the optimal time condition of TRx therapy such 
as gene delivery of TRx to overcome various cardiovascular 
diseases related with EC pathology in animal models. 
Subjects and Methods
Cell culture
hEPCs were isolated from human peripheral blood with 
minor modification of the protocol of Kalka et al.
13) Briefly, 
the mononuclear cells were fractionated from other compo-
nents of peripheral blood by centrifugation at 1,200 rpm for 
10 minutes on Histopaque-1077 (Sigma-Aldrich Co., St. Louis, 
MO, USA) gradients according to manufacturer’s instruc-
tions. Isolated mononuclear cells were resuspended using an 
EGM-2 BulletKit system (Lonza Ltd., Basel, Switzerland) 
consisting of endothelial basal medium, 5% fetal bovine se-
rum (FBS), human endothelial growth factor, vascular endo-
thelial growth factor, human fibroblast growth factor-B, in-
sulin-like growth factor-1, ascorbic acid and heparin. Mono-
nuclear cells were seeded at 1×10
7 cells per well on 2% gelatin-
coated six-well plates (Sigma-Aldrich Co.). The media was 
changed on the 6th day after plating and every 3 days there-
after. Each cluster or colony was observed microscopically 
daily. Cells were passaged at confluence following dissocia-
tion with 0.05% trypsin and grown for 3 days in fresh medi-
um which was consisted of M199 (Sigma-Aldrich Co.) sup-
plemented with 10% FBS and antibiotics or the EGM-2 Bul-
letKit system.
HUVECs were isolated from human umbilical veins, as pre-
viously described.
14) Umbilical cords were immersed into a 
culture dish and carried to the cell culture room. Both ends of 
the cord were bound and the ends of the umbilical vein were 
cannulated. The vein was washed through the cannula by ste-
rile phosphate buffered saline (PBS). Then, the vein was filled 
with 0.02% collagenase in PBS, and placed in a CO2 incuba-
tor for 10 minutes at 37°C. HUVECs were isolated in centri-
fuge tube from the vessel by two times of washing with 10 
mL M199. Cell suspension was centrifuged at 1,200 rpm for 
10 minutes, and the supernatant was discarded and the cells 
were resuspended with EGM-2 BulletKit system on 2% gel-
atin-coated six-well culturing plates. Cells were passaged at 
confluence following dissociation with 0.05% trypsin and 
grown for 3 days in fresh medium which was consisted of 
M199 supplemented with 10% FBS and antibiotics or EGM-
2 BulletKit system.
Generation of hypoxic conditions
To induce the hypoxic condition in the two EC lines, cul-
tured hEPC and HUVEC were placed in the GasPak
TM pouch 
system (BD, Franklin Lakes, NJ, USA) according to the man-
ufacturer’s instructions. The GasPak pouch system was main-
tained in a CO2 incubator 37°C until cell harvesting at 6, 12, 
24, 36, 48, 60 and 72 hours. 
Quantitative measurement of apoptosis 
by fluorescence-activated cell sorting
Cultured hEPC and HUVEC were processed with the An-
nexin V: Phycoerythrin (PE) Apoptosis Detection Kit I (BD). 
The Annexin V: PE Kit was used to assess cell membrane in-
tegrity; 7-Aminoacetinomycin D (AAD, BD) was used to as-
sess cell membrane permeability, and thus cell apoptosis. In 
brief, collected hEPC and HUVEC were washed twice with 
cold PBS and then resuspended in the binding buffer (10 mM 
HEPES, 140 mM NaCl, 2.5 mM CaCl2, pH 7.4) at a concen-
tration 5×10
6 cell/mL. After these mixtures were transferred 
to a 5 mL culture tube, 5 μL of Annexin-V and 7-AAD were 
added. After gentle vortexing, cells were incubated for 10 
minutes at room temperature in the dark and analyzed by 
fluorescence-activated cell sorting (FACS). The FACSCali-
bur-S (BD) was equipped with an argon ion laser system 
which was adjusted to 488 nm excitation and 578 nm maxi-
mum emission. FACS analysis was performed 4 times on each Keon-Jae Park, et al.   653
cell line and time point. Results were depicted as mean±stan-
dard deviation (SD). The proportion of apoptosis in the con-
trol (baseline time) was described as 100% in each cell line, 
the percent change in degree of apoptosis at each observation 
time was calculated and depicted by comparing it to apopto-
sis in the control. 
Western blot analysis
To examine the expression pattern of the TRx system in hEP-
Cs and HUVECs which were stressed by hypoxia, we perform-
ed a Western blot analysis. Harvested hEPCs and HUVECs 
were immersed in PRO-PREP Protein Extraction Solution 
(iNtRON Biotechnology, Seongnam, Korea) and incubated at 
4°C for 2 hours. The extracts were centrifuged with 12,000 rpm 
at 4°C for 15 minutes to remove insoluble material. Protein 
concentrations were determined using the Bio-Rad protein 
assay kit (Bio-Rad Laboratories, Hercules, CA, USA). Equal 
amounts of total protein (20 μg) were diluted with sample buf-
fer containing 100 mM dithiothreitol and heated to 98°C for 
5 minutes and subjected to 10% sodium dodecyl sulfate-po-
lyacrylamide gel electrophoresis in a gel apparatus (Hoefer, 
Holliston, MA, USA), subsequently transferred to polyvinyli-
dene fluoride membranes according to the method of Ger-
shoni and Palade
15) Blots were blocked with 5% skim milk in 
Tris-Buffered Saline Tween-20 (TBST) for 2 hours (at RT or 
4°C). The membrane was incubated with antibodies against 
TRx, TRxR, TxNip, Bcl-2, Bax-α, Akt, Survivin (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA). The antibodies were di-
luted 1 : 2,000 in TBST, incubated, shaking, at room temper-
ature for 1 hour, washed in TBST, and incubated with horse-
radish peroxidase-conjugated secondary antibody (1 : 2,000-
1 : 5,000) for 1 hour. After washing, blots were developed us-
ing the West-Zol kit (iNtRON Biotechnology) for 1 minute 
and chemiluminescence was detected using the LAS-3000 (Fu-
jifilm, Minato, Tokyo, Japan) for 10-300 seconds. Optical den-
sity (OD) was evaluated by the MultiGauge Ver 3.1 (Fujifilm) 
program. ODs were calculated 5 times for each result and ex-
pressed as mean±SD. OD in the control (baseline time) was 
described as 100% in each cell line, and the percent change in 
OD at each observation time was calculated and depicted by 
comparing it to the OD of the control. 
Reverse transcription-polymerase chain reaction 
for thioredoxin messenger ribonucleic acid
expression
Total ribonucleic acid (RNA) was extracted from cultured 
cells using TRIzol
® Reagent (Invitrogen, San Diego, CA, USA) 
according to the manufacturer’s instructions. Gene-specific 
primers for the human TRx gene (forward, 5’-TTCTTTCAT 
TCCCTCTGTG-3’; reverse, 5’-TCCGTAATAGTGGCTT 
CG-3’) and human glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) (forward, 5’-ATGGGGAAGGTGAAGGTCG 
Fig. 1. Apoptosis in hEPC and HUVEC during hypoxia via FACS analysis. Hypoxia generated by the GasPak system, hEPC showed bimodal 
peaks of apoptosis at 12 and 24 hours (175.9±35.8%, 398.3±75.8%), 60 and 72 hours (220.5±68.1%, 368.8±20.3%) of hypoxia. HUVECs 
showed increased apoptosis at 12 hours (256.3±42.2%) of hypoxia initially and the highest degree of apoptosis was observed at 72 hours 
(500.6±45.6%) of hypoxia. *Significantly different from the control time (p<0.05). hEPC: human endothelial progenitor cells, HUVEC: human 
umbilical vein endothelial cells, FACS: fluorescence-activated cell sorting.  
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GAGTC-3’; reverse, 5’-CCATGCCAGTGAGCTTCCCGT 
TC-3’) were synthesized (BIONEER, Daejeon, Korea). RNA 
template and primers mixed Maxime
TM reverse transcrip-
tion-polymerase chain reaction PreMix (iNtRON). PCR prod-
ucts were separated on a 1.5% agarose gel and imaged on an 
SL-20 deoxyribonucleic acid Image Visualizer (SeouLin Bio-
science, Seoul, Korea). ODs were evaluated using the Multi-
Gauge Ver 3.1 (Fujifilm) program. Each OD was calculated 
3 times and expressed as mean±SD. The OD of the control 
(baseline time) was describe as 100% in each cell line, percent 
change in OD at each observation time was calculated and 
depicted by comparing each to the OD of the control. 
Results 
Apoptosis in human endothelial progenitor cells 
and human umbilical vein endothelial cells 
under hypoxic stress 
The pattern of cellular apoptosis was examined with the An-
nexin V: PE FACS in hEPC and HUVEC along with the dura-
tion of hypoxia. hEPC showed the typical bimodal peaks of 
the apoptosis pattern during hypoxia. At 12 and 24 hours af-
ter the initiation of hypoxia, the proportion of apoptotic hEP-
Cs increased steeply to 175.9±35.8%, and 398.3±75.8%, re-
spectively, compared with nonhypoxic control cells (100± 
23.7%, p<0.05 at 12 and 24 hours) (Fig. 1). The level of apop-
tosis at 36 and 48 hours of hypoxia was significantly decre-
ased when compared with that at 24 hours of hypoxia; how-
ever, the level of apoptosis had increased at 60 and 72 hours of 
hypoxia when compared with control (220.5±68.1%, 368.8± 
20.3%, p<0.05) (Fig. 1). 
The apoptosis pattern of HUVECs under hypoxic stress was 
slightly different from that of hEPCs. The initial peak of apop-
tosis occurred at 12 hours of hypoxia, (256.3±42.2%) compar-
ed with control cells (100±25.2%, p<0.05). Apoptosis was de-
creased to nadir at 36 hours of hypoxia, after which the level 
of apoptosis increased again up to 315.2±42.3% at 48 hours, 
202.3±36.9% at 60 hours, and 500.6±45.6% at 72 hours of 
hypoxia (Fig. 1).
Expression of the thioredoxin system in human 
endothelial progenitor cells and human umbilical 
vein endothelial cells under hypoxia stress
TRx expression in hEPCs was significantly increased com-
pared with control at 12 hours (651.3±78.5% vs. 100.0±24.5%, 
p<0.05) to 72 hours of hypoxia (898.7±145.2% vs. 100±24.5%, 
p<0.05) (Fig. 2). TRxR expression remained low up to 36 
hours under hypoxia, but had increased abruptly at 48 hours 
when compared with control (1,320.1±127.9% vs. 100±24.2%, 
p<0.05) (Fig. 2). 
In HUVECs under hypoxic stress, three significant peaks of 
TRx expression were noticed at 12, 36, and 72 hours of hy-
poxia (640.1±89.4%, 620.2±98.1%, 595.9±128.4% vs. 100± 
19.7%, p<0.05 compared to control at each time point) (Fig. 
Fig. 2. The expression pattern of the TRx system in hEPCs and HUVECs during hypoxia. In hEPCs during hypoxia, TRx expression was el-
evated at 12 and 24 hours (651.3±78.5%, 593.5±64.3%) and thereafter. In HUVECs, TRx expression was increased at 12, 36, and 72 hours 
of hypoxia (640.1±89.4%, 620.2±98.1%, 595.9±128.4% on each time point), but the over-expression of TRxR and TxNip was not observed 
during whole hypoxic period. The TRx/TxNip ratio was increased at 36 hours (250.8±77.8%) of hypoxia in hEPCs and at 48 and 72 hours 
(301.7±49.2%, 550.4±78.4%) of hypoxia in HUVECs. *Significantly different from the control time (p<0.05). TRx: thioredoxin, hEPC: human en-
dothelial progenitor cells, HUVEC: human umbilical vein endothelial cells, TRxR: TRx reductase, TxNip: TRx interacting protein.
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2). TxNip in HUVECs under hypoxia showed apattern of 
expression similar to that of TRx from 12 to 48 hours of hy-
poxia, but nadir expression was continued thereafter. TRxR 
expression in HUVECs decreased steadily during the period 
of hypoxic stress. 
The TRx/TxNip ratio, a marker of TRx system activation in 
hypoxia, showed different patterns in the 2 EC lines. In hEPCs, 
the TRx/TxNip ratio was significantly increased at 36 hours 
of hypoxia compared with control (250.8±77.8% vs. 100± 
35.4%, p<0.05) (Fig. 2). In HUVECs, the TRx/TxNip ratio st-
eadily increased from 6 hours onward, and was significantly 
increased at 48 hours and 72 hours when compared with con-
trol (301.7±49.2%, 550.4±78.4% vs. 100±24.3%, p<0.05 on 48, 
72 hours) (Fig. 2).
Thioredoxin messenger ribonucleic acid expression
in human endothelial progenitor cells and human
umbilical vein endothelial cells under hypoxic stress
The temporal expression patterns of these 2 EC lines un-
der hypoxic stress were very distinct. hEPCs showed signifi-
cant increases in TRx messenger ribonucleic acid (mRNA) ex-
pression at 24, 36, and 48 hours of hypoxia compared with 
control (193.5±56.3%, 188.7±65.9, 205.9±61.2% vs. 100±20.0%, 
p<0.05 at each time point) (Fig. 3). No distinct changes in ex-
pression of TRx mRNA were observed in HUVECs (Fig. 3). 
Expression of Bax and Bcl-2 in human endothelial
progenitor cells and human umbilical vein 
endothelial cells under hypoxic stress
In hEPCs under hypoxic stress, Bcl-2 expression was mark-
edly increased at 12 and 60 hours of hypoxia (182.7±48.3%, 
189.5±52.9% vs. 100±24.2%, p<0.05 at each time point) (Fig. 4). 
Lower values of Bcl-2 expression were observed from 24 to 
48 hours and 72 hours of hypoxia, which was well correlated 
with the degree of apoptosis seen in hEPCs. 
In HUVECs, Bcl-2 expression was higher at 6, 12, 36, 60, 
72 hours of hypoxia (259.4±44.9%, 243.4±38.7%, 274.8±46.8%, 
220.9±49.7%, 279.3±50.1% vs. 100±7.96%, p<0.05 at each 
time point) and the expression of Bax was similar.
The Bax/Bcl-2 ratio, as a marker of apoptosis/survival, show-
ed a similar pattern during hypoxia stress in the two cell lines. 
However, significantly higher values were observed in hEPCs 
at 24 (212.4±67.0% vs. 110.8±48.3%, p<0.05) and 60 hours 
(275.9±86.3% vs. 89.5±59.1%, p<0.05) of hypoxia when com-
pared with HUVECs (Fig. 4).
 
The expression pattern of Caspase 3, Akt, and 
Survivin in human endothelial progenitor cells and
human umbilical vein endothelial cells 
under hypoxic stress
Only slight increases in the expression of caspase 3 in hEPCs 
were observed at 12 and 60 hours of hypoxia. Survivin expres-
sion was increased at 12 hours of hypoxia. Akt expression in-
creased during the whole period of hypoxia in hEPCs. 
Slight and steady increases of caspase 3 expression in HU-
VECs were observed, with expression at 48, 60, 72 hours of hy-
poxia significantly elevated compared with control at these 
time points (196.8±45.9%, 276.7±78.2%, 289.6±89.4% vs. 
100±24.1%, p<0.05) (Fig. 5). Akt was significantly over-ex-
pressed from 24 hours of hypoxia and thereafter; and elevat-
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Fig. 3. TRx mRNA expression in hEPCs and HUVECs during hypoxic stress. TRx mRNA expression was increased significantly from 24 hours 
and thereafter during hypoxia in hEPCs (193.5±56.3%, 188.7±65.9%, 205.9±61.2% on 24, 36, 47 hours), but no increase in TRx mRNA ex-
pression in HUVECs was evident during the whole hypoxic period. *Significantly different from the control time (p<0.05). TRx: thioredoxin, mRNA: 
messenger ribonucleic acid, hEPC: human endothelial progenitor cells, HUVEC: human umbilical vein endothelial cells.
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Fig. 4. The expression pattern of Bax and Bcl-2 in hEPCs and HUVECs during hypoxia. In hEPC, Bcl-2 expression showed 2 peaks at 12 and 
60 hours (182.7±48.3%, 189.5±52.9%) of hypoxia, Bax expression was not increased significantly. In HUVECs, there were 3 peaks of Bcl-2 ex-
pression at 6 to 12, 36, and 60 to 72 hours (259.4±44.9%, 243.4±38.7%, 274.8±46.8%, 220.9±49.7%, 279.3±51.1% on each time point) of hy-
poxia and the Bax expression pattern was similar. Higher values of the Bax/Bcl-2 ratio were observed at 24 hours (212.4±67.0% vs. 110.8± 
48.3%) and 60 hours (275.9±86.3% vs. 89.5±59.1%) of hypoxia in hEPCs compared with HUVECs. *Significantly different from the control time 
(p<0.05), †Significantly different between hEPC and HUVEC (p<0.05). hEPC: human endothelial progenitor cells, HUVEC: human umbilical 
vein endothelial cells.
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Fig. 5. The expression pattern of Caspase 3, Akt, and Survivin in hEPCs and HUVECs during hypoxia. A steep increase in the expression of Akt 
was observed in hEPC and HUVECs. Akt overexpression was significantly increased compared with control starting at 12 hours of hypoxia in hEP-
Cs and starting at 24 hours of hypoxia in HUVECs. Caspase 3 and survivin activation was not evident in hEPCs during whole hypoxic period. 
Caspase 3 overexpression in HUVECs was observed starting at 48 hours (196.8±45.9%) of hypoxia. Higher survivin expression was observed 
at 12, 60, and 72 hours (385.7±75.2%, 345.6±89.1%, 678.7±95.7% on each time point) of hypoxia in hEPCs. *Significantly different from the control 
time (p<0.05). hEPC: human endothelial progenitor cells, HUVEC: human umbilical vein endothelial cells, mRNA: messenger ribonucleic acid.
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ed expression of survivin was observed at 12, 60, and 72 hours 
of hypoxia in HUVECs (Fig. 5). Grossly, the expression pat-
terns of these 3 proteins were very similar between two ECs 
lines (Fig. 5). 
Discussion
ECs have putative roles in maintaining the vascular homeo-
stasis. ECs lining the vascular endothelium release various va-
sodilators, including NO and prostacyclin, as well as several 
kinds of vasoconstrictors.
15) ECs also control the intravascular 
coagulation-fibrinolysis system to maintain a non-thrombotic 
milieu. 
Endothelial dysfunction is an early pathologic feature in car-
diovascular diseases. An imbalance between oxidative stress 
and the anti-oxidative system in ECs is a common underlying 
cause of cardiovascular disease. Several lines of evidence have 
accumulated that support an important role for oxidative st-
ress in the pathogenesis and aggravation of various cardiovas-
cular diseases, such as hypertension, dyslipidemia, diabetes mel-
litus, atherosclerosis, ventricular hypertrophy, ischemic heart 
disease, and heart failure.
16-20) The susceptibility of cell lines of 
cardiovascular tissues such as EC, cardiomyocytes, and fibro-
blasts to oxidative stress depends on the balance between the 
generation of ROS, described earlier, and the scavenging ac-
tivity of the antioxidative system. One important antioxida-
tive mechanism in mammalian cells is the TRx system which 
is a thiol reducing system that acts against ROS, especially 
NO and H2O2. 
TRx is a small, ubiquitous thiol protein and is one of the im-
portant regulators of the reduction-oxidation balance and re-
dox-controlled cell functions. Regulation of TRx is closely 
correlated with the control of cellular redox balance, the pro-
motion of cell growth, the inhibition of apoptosis, and the mo-
dulation of inflammation. The redox activity of TRx totally 
depends on two cystein residues of Cys32 and Cys35.
21) The 
two cystein residues exist as a dithiol in the reduced form and 
a disulfide in the oxidized form. TRx is oxidized when it tr-
ansfers reducing equivalents to disulfide groups in target pro-
teins and it is reduced back to the dithiol form by an NAD-
PH-dependent protein, TRxR.
22) Moreover, TRx is expressed 
prominently in ECs and protects ECs from H2O2-induced cy-
totoxicity.
23) ROS induce TRx expression in ECs and low con-
centrations of H2O2 protect ECs from apoptosis via overex-
pression of TRx.
24) 
Another important molecule in the TRx system is TxNip. 
It inhibits TRx activity by interacting with the catalytic site 
of TRx, suggesting that TxNip is an endogenous inhibitor of 
TRx.
25) Hyperglycemia induces overexpression of TxNip in 
vascular tissue and reduces TRx activity,
26) implicating a role 
for oxidative stress in diabetes TxNip also has important role 
in cardiovascular disorders and acts as a sensor for biome-
chanical and oxidative stress.
27) Therefore, the antioxidative 
capability of the TRx system mainly depends on the action 
and expression pattern of TRx, TRxR, and TxNip. In hEPCs, 
TRx expression rapidly increased at 12 hours of hypoxia and 
this time point was closely related with increased apoptosis 
in these cells. However, the increase in TRx mRNA expression 
was also observed at 24 hours of hypoxia, making the interval 
from 12 to 24 hours of hypoxia was exhausted period of TRx 
and higher apoptosis on 24 hours of hEPC could be analo-
gized.
TxNip is an endogenous inhibitor of TRx, so the TRx/TxNip 
ratio can be used as an gross indicator for the antioxidative 
capacity of the TRx system. The TRx/TxNip ratio in hEPCs sh-
owed its lowest level up to 36 hours of hypoxia and this peri-
od could be considered as the utilization phase of the cyto-
solic form of TRx. The mRNA level of TRx was elevated at 24 
hours of hypoxia and marked TRx elevation was observed at 
36 hours of hypoxia at a level which could prevent hEPC apo-
ptosis. 
In HUVECs, there were three peaks of TRx expression at 
12, 36, and 72 hours of hypoxia. These patterns of TRx expres-
sion were relatively well correlated with increases in apopto-
sis in HUVECs. The expression of TRxR was reduced com-
pared with control and the expression of TxNip was also not 
evident during whole period of hypoxia in HUVECs. The ex-
pression of TRx mRNA and TRx protein during hypoxia in 
HUVECs showed marked discrepancy and the expression pat-
tern of TRx in the two cell lines was also very distinct. 
The TRx/TxNip ratio in HUVECs showed two peaks at 48 
and 72 hours of hypoxia, a pattern that was relatively well ma-
tched with the apoptosis pattern in HUVECs. Contrary to 
hEPCs, the TRx and TRx/TxNip ratio was well correlated with 
the degree of apoptosis in HUVECs, but not with apoptosis 
prevention. The higher Bax/Bcl-2 ratio in HUVECs was ob-
served at 24 and 60 hours of hypoxia, and a lower Bax/Bcl-2 
ratio was observed at 6 and 48 hours of hypoxia; these find-
ing were relatively well correlated with the degree of apopto-
sis in HUVECs during hypoxia. According to these findings, 
the TRx system expression pattern shown was relatively well 
correlated with the degree of cellular apoptosis and expres-
sion pattern of cell death and survival of hEPCs in hypoxia, 
but, the temporal relationship of the expression pattern of 
TRx system in HUVECS was less well correlated with the de-
gree of apoptosis, and cell survival signaling in HUVECs dur-
ing hypoxia. Therefore, the responses of the TRx antioxidative 
system during hypoxia are slightly different in the two cell types.
There are many kinds of cellular antioxidative systems in the 
cell membrane, cytosol, and mitochondria. We think that each 
cell line has peculiar antioxidative capability composed of 
complex mixture of various kinds of antioxidative systems. 
Even in similar forms of human EC lines, the TRx system may 
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hEPC and HUVEC in hypoxic condition. These considerations 
may give us some solutions for the different apoptotic degree, 
survival signaling in used 2 cell lines. Up to now, there are 
many data of the relationship between oxidative stress/anti-
oxidative system and cardiovascular disease, such as hyperten-
sion, left ventricular hypertrophy/remodeling, heart failure and 
atherosclerosis.
23)25-28) But, the decisive data for the causal-con-
sequence relationship of those are limited. That problem may 
be originated from the complexity and non-specificity of oxi-
dative stress and antioxidative system in various disease models.
Our data clearly shows the relationship between the TRx 
system and apoptosis in ECs during hypoxia. However, the 
molecular position of the TRx system in the causal-conse-
quence relationship in hypoxia-induced apoptosis is still un-
known. To exploit the direct evidence of the impact of the TRx 
system on hypoxia-induced apoptosis in ECs, further analy-
sis is needed, including using small interfering ribonucleic 
acid, chemical inhibitos, or an overexpression model of the 
TRx system of both in vitro cell and in vivo animal models 
of hypoxia.
29) If the role of the TRx system in ECs during hy-
poxia could be elucidated, it could yield new therapeutic tar-
gets for cardiovascular disease involving the TRx system.
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